INTRODUCTION {#s1}
============

Type 2 diabetic mellitus (T2DM) is the predominant type of diabetic mellitus which is a complex metabolic disorder with hereditary and environmental factors.\[[@R1]\] Coronary artery disease (CAD) is also a multifactorial and polygenic disorder. The emergency of CAD is two to four times more frequent in diabetic patients than non-diabetic subjects, which implies the hidden mechanism of CAD risk in T2DM groups.\[[@R2]\] The serum levels of adiponectin, an adipocyte-derived hormone, are indicated to be associated with different metabolic syndrome \[[@R3]\], including obesity \[[@R4]\], type 2 diabetes \[[@R5]\], and insulin resistance \[[@R6]\]. And low plasma levels of adiponectin has been shown to be related with CAD risk.\[[@R7]--[@R9]\]

The gene coding for adiponectin, ADIPOQ, is located on chromosome 3q27, which is the susceptible locus for CAD and T2DM.\[[@R10], [@R11]\] A wide range of anti-athergenic effects of adiponectin is reported.\[[@R12]\] Its genetic deficit could increase the risk of CAD in both general population and patients with type 2 diabetes.\[[@R13]\] Since plasma adiponectin level is affected by genetic factors such as single-nucleotide polymorphisms in the adiponectin gene (ADIPOQ), many studies about the associations between the polymorphisms of ADIPOQ and CAD, T2DM, Obesity and insulin resistance have been reported. And the SNPs of the adiponectin gene are reported to be associated with CAD and T2DM.\[[@R5], [@R8], [@R14]\]

The polymorphisms of rs2241766 and rs1501299 are two common single nucleotide polymorphisms of ADIPOQ. The rs2241766 polymorphism is a T/G substitution in exon2 and the rs1501299 is a G/T substitution in intron2. The influence of the two SNPs on CAD have been investigated in patients with T2DM, \[[@R15]--[@R17]\] the results are inconsistent. In the study of Bacci et al. \[[@R18]\] and Filippi et al.\[[@R19]\], no association was found between the rs2241766 polymorphism and CAD risk in T2DM patients. However, significant association was reported by Ma et al.\[[@R20]\] For the rs1501299 polymorphism, a protective role was reported in the study of QI et al.\[[@R21], [@R22]\] But an increased risk was reported by Mohammadzadeh et al.\[[@R23]\] The small numbers and various populations of the published studies may partially account for the controversial results. Our meta-analysis therefore aims to pool current evidence together for better understanding of the potential associations between the rs2241766 and rs1501299 polymorphisms and CAD risk in type 2 diabetic patients.

RESULTS {#s2}
=======

The characteristics of the include studies {#s2_1}
------------------------------------------

214 articles were obtained by online and manual search. After removing duplicates and screening title and abstract, eighty articles were included. Seven articles were excluded for lack of detailed genotype distribution. Finally, a total of twelve published articles, \[[@R11], [@R18], [@R20]--[@R23], [@R29]--[@R34]\] involving 3996 cases and 8876 controls were included in this meta-analysis (Seen in the [Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

The characteristics of all the included articles are summarized in Table [1](#T1){ref-type="table"}. For rs2241766, twelve studies are included with 2136 cases and 3391 controls; ten studies with 1860 cases and 5485 controls are included for rs1501299.

###### Characteristics of included studies selected for meta-analysis

  Study               Year   Country        Enthicity   Region            Sample size   Genotype distributions in cases/controls   Genotyping   Quality   HWE\*                   
  ------------------- ------ -------------- ----------- ----------------- ------------- ------------------------------------------ ------------ --------- -------- ---------- --- -------
  rs2241766                                                                                                                                                                       
  Mohammadzadeh       2016   Iran           Caucasian   Western Asian     100           100                                        75/65        24/31     1/4      PCR-RFLP   8   0.899
  Mofarrah            2016   Iran           Caucasian   Western Asian     152           72                                         82/56        35/13     35/3     PCR-HRM    8   0.072
  Esteghamati         2012   Iran           Caucasian   Western Asian     114           127                                        48/68        41/46     25/13    PCR-RFLP   7   0.222
  Nan                 2012   China          Mongoloid   Eastern Asian     213           467                                        115/237      84/191    14/39    PCR-HRM    8   0.952
  Al-Daghri           2011   Saudi Arabia   Caucasian   Western Asian     122           298                                        77/220       35/72     10/6     PCR-RFLP   7   0.969
  Chiodini            2010   Italy          Caucasian   Southern Europe   499           503                                        321/359      168/126   10/18    Taqman     8   0.102
  Ma                  2008   China          Mongoloid   Eastern Asian     159           31                                         94/12        55/16     10/3     PCR-RFLP   8   0.479
  Qi                  2006   China          Mongoloid   Eastern Asian     266           672                                        204/529      62/143             Taqman     8   \-
  Qi                  2005   China          Mongoloid   Eastern Asian     219           599                                        170/440      49/159             Taqman     8   \-
  Lacquemant Swiss    2004   Switzerland    Caucasian   Northern Europe   107           181                                        76/145       27/34     4/2      PCR        8   0.997
  Lacquemant French   2004   Switzerland    Caucasian   Northern Europe   55            130                                        27/57        25/65     3/8      PCR        7   0.059
  Bacci               2004   Italy          Caucasian   Southern Europe   130           211                                        90/140       35/60     5/11     PCR        8   0.182
                                                                                                                                                                                  
  rs1501299                                                                                                                                                                       
  Mohammadzadeh       2016   Iran           Caucasian   Western Asian     100           100                                        38/56        55/42     7/2      PCR-RFLP   9   0.063
  Katakami            2012   Japan          Mongoloid   Eastern Asian     213           2637                                       129/1358     71/1047   13/232   PCR        8   0.139
  Esteghamati         2012   Iran           Caucasian   Western Asian     114           127                                        76/63        30/47     8/17     PCR        8   0.095
  Al-Daghri           2011   Saudi Arabia   Caucasian   Western Asian     123           297                                        47/111       57/142    19/44    PCR-RFLP   7   0.897
  Chiodini            2010   Italy          Caucasian   Southern Europe   499           503                                        271/239      189/198   39/66    Taqman     8   0.016
  Qi                  2006   China          Mongoloid   Eastern Asian     280           684                                        159/374      104/258   17/52    Taqman     8   0.420
  Qi                  2005   China          Mongoloid   Eastern Asian     228           594                                        105/293      111/249   12/52    Taqman     8   0.930
  Lacquemant Swiss    2004   Switzerland    Caucasian   Southern Europe   106           179                                        57/96        40/65     9/18     PCR        7   0.166
  Lacquemant French   2004   Switzerland    Caucasian   Northern Europe   55            130                                        25/73        26/50     4/7      PCR        8   0.679
  Bacci               2004   Italy          Caucasian   Southern Europe   142           234                                        70/118       65/83     7/28     PCR        7   0.031

For rs2241766 variant, 11, 12 and 22 represent TT, GT, GG, respectively; for rs1501299 variant, 11, 12 and 22 represent GG, TG and TT, respectively.

\* *P* value for Hardy--Weinberg equilibrium test in controls

Meta-analysis results {#s2_2}
---------------------

### ADIPOQ rs2241766 polymorphism and CAD risk in T2DM patients {#s2_2_1}

Table [2](#T2){ref-type="table"} showed the results of this meta-analysis for ADIPOQ rs2241766 polymorphism and CAD in diabetic patients. The rs2241766 polymorphism showed no significant associations with CAD in type 2 diabetic group based on combined results from all studies. Besides, significant heterogeneity was found. Sensitivity analysis was performed by sequentially omitting 1 individual study at a time, but heterogeneity was still significant in five genetic models. Subgroup analysis was introduced for further study, and significant associations were found in different subgroups. Our results showed that rs2241766 polymorphism was associated with decreased risk of CAD in recessive model (GG VS GT+TT: OR=0.45,95%CI=0.27-0.73,P~h~=0.001) in the subgroup of sample size(more than 500)(Figure [1](#F1){ref-type="fig"}), but increased risk of CAD was found in the subgroup of genotyping method(PCR-RFLP) in recessive model (GG VS GT+TT: OR=2.05, 95%CI=1.23-3.39, P~h~=0.005)(Figure [2](#F2){ref-type="fig"}). In the Caucasian subgroup, increased risk was also detected in heterozygote model (CT VS TT: OR=1.19, 95%CI=1.00-1.42, Ph=0.89) (Figure [3](#F3){ref-type="fig"}).

###### Meta-analysis results of the associations between rs2241766 and rs1501299 polymorphisms in ADIPOQ gene and CAD risk in T2DM patients

  Genetic model   NO. of studies   OR\[95%CI\]               P~meta-analysis~   Bon         FDR         *I*^2^ (%)   P^a^~heterogeneity~   Statistical method
  --------------- ---------------- ------------------------- ------------------ ----------- ----------- ------------ --------------------- --------------------
  rs2241766                                                                                                                                
  G VS T          12               1.18 \[0.89, 1.56\]       0.260              1.000       0.613       80.00        0.000                 Random
  GG VS GT+TT     12               1.21 \[0.56, 2.61\]       0.630              1.000       0.630       81.00        0.000                 Random
  GG+GT VS TT     12               1.11 \[0.88, 1.39\]       0.390              1.000       0.613       68.00        0.000                 Random
  GT VS TT        12               1.08 \[0.86, 1.37\]       0.490              1.000       0.613       52.00        0.030                 Random
  GG VS TT        12               1.33 \[0.69, 2.55\]       0.400              1.000       0.613       72.00        0.000                 Random
  rs1501299                                                                                                                                
  T VS G          10               **0.86 \[0.76, 0.98\]**   **0.020**          0.100       **0.033**   46.00        0.060                 Fixed
  TT VS TG+GG     10               0.40 \[0.22, 0.71\]       0.002              0.010       0.005       84.00        0.000                 Random
  TT+TG VS GG     10               0.95 \[0.78, 1.16\]       0.600              1.000       0.600       63.00        0.003                 Random
  TG VS GG        10               0.95 \[0.79, 1.13\]       0.530              1.000       0.600       45.00        0.070                 Fixed
  TT VS GG        10               **0.67 \[0.54, 0.83\]**   **0.000**          **0.002**   **0.002**   36.00        0.120                 Fixed

OR= odd ratio; CI= confidence interval.

^a^ *P* value for between-study heterogeneity based on Q test;Bon= p value in Bonferroni test; FDR= false discovery rate.

Significant results are marked in bold.
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### ADIPOQ rs1501299 polymorphism and CAD risk in T2DM patients {#s2_2_2}

The results of associations between ADIPOQ rs150299 polymorphism and CAD risk in type 2 diabetic subjects were showed in Table [3](#T3){ref-type="table"}. A decreased risk of rs1501299 was only detected in homozygote model (TT VS GG: OR=0.67, 95%CI=0.54-0.83, Ph=0.0003), and significant heterogeneity were found in the other four genetic models. Therefore, sensitivity analysis was conducted to explore the source of heterogeneity. Heterogeneity were significant decreased in the allelic model, dominant model and heterozygote model when Mohammadzadeh et al.\[[@R23]\] was moved out. A decreased risk was detected in allelic model (T VS G: OR=0.86, 95%CI=0.76-0.98, Ph=0.02) (Figure [4](#F4){ref-type="fig"}). Besides, a decreased risk was also found in recessive model (TT VS TG+GG: OR=0.47, 95%CI=0.33-0.67, Ph=0.000) (Figure [5](#F5){ref-type="fig"}) when Katakami et al.\[[@R32]\] was moved out.

###### Results of subgroup analysis for ADPIOQ rs2241766 polymorphisms and CAD in type 2 diabetic patients

                          G VS T   GG+GT VS TT         GG VS GT+TT   GT VS TT            GG VS TT                                                                                            
  ----------------------- -------- ------------------- ------------- ------------------- ---------- ----------------------- ------------- ------------------- ---------- ------------------- ----------
  **Total**               10       1.18\[0.89,1.56\]   80/0.000      1.11\[0.88,1.39\]   68/0.000   1.21\[0.56,2.61\]       81/0.000      1.14\[0.98,1.32\]   52/0.030   1.33\[0.69,2.55\]   72/0.000
  **Enthicity**                                                                                                                                                                              
  Caucasian               8        1.32\[1.15,1.51\]   78/0.000      1.30\[0.97,1.73\]   64/0.007   1.57\[1.13,2.18\]       79/0.000      1.26\[1.06,1.49\]   32/0.17    1.74\[1.23,2.46\]   72/0.000
  Mongoloid               2        0.82\[0.65,1.04\]   49/0.160      0.86\[0.66,1.13\]   43/0.15    0.63\[0.37,1.06\]       89/0.003      0.82\[0.60,1.11\]   61/0.11    0.68\[0.38,1.25\]   0/0.490
  **Region**                                                                                                                                                                                 
  Eastern Asian           2        0.82\[0.65,1.04\]   49/0.160      0.89\[0.73,1.07\]   43/0.15    0.63\[0.37,1.06\]       89/0.003      0.82\[0.60,1.11\]   61/0.110   0.67\[0.37,1.21\]   0/0.49
  Western Asian           4        1.66\[1.34,2.06\]   85/0.000      1.51\[1.16,1.96\]   76/0.005   3.27\[2.04,5.22\]       77/0.004      1.21\[0.91,1.62\]   40/0.17    2.97\[1.10,8.03\]   65/0.040
  Southern Europe         2        1.11\[0.91,1.36\]   49/0.160      1.24\[0.98,1.56\]   64/0.10    0.53\[0.28,1.00\]       0/0.790       1.32\[1.04,1.68\]   66/0.09    0.65\[0.34,1.23\]   0/0.85
  Northern Europe         2        1.19\[0.84,1.68\]   70/0.07       1.20\[0.79,1.82\]   63/0.10    0.75\[0.28,2.05\]       54/0.140      1.15\[0.75,1.76\]   50/0.16    1.60\[0.35,7.42\]   48/0.16
  **Sample Size**                                                                                                                                                                            
  More than 500           2        1.05\[0.88,1.25\]   69/0.07       1.07\[0.91,1.25\]   60/0.060   **0.45\[0.27,0.73\]**   **0/0.450**   1.22\[0.99,1.51\]   80/0.030   0.69\[0.42,1.14\]   0/0.74
  less than 500           8        1.29\[1.10,1.51\]   82/0.000      1.21\[0.99,1.46\]   73/0.000   2.10\[1.47,3.00\]       75/0.000      1.06\[0.87,1.31\]   45/0.080   2.07\[1.41,3.04\]   69/0.002
  **Genotyping Method**                                                                                                                                                                      
  PCR-RFLP                4        1.04\[0.58,1.87\]   85/0.000      1.12\[0.85,1.47\]   78/0.003   **2.05\[1.23,3.39\]**   **32/0.22**   0.99\[0.74,1.33\]   62/0.050   1.96\[1.15,3.32\]   74/0.008
  PCR-HRM                 2        1.71\[0.45,6.59\]   95/0.000      1.15\[0.87,1.53\]   91/0.000   1.33\[0.86,2.05\]       97/0.000      1.04\[0.77,1.41\]   67/0.080   1.55\[0.95,2.54\]   92/0.000
  PCR                     3        1.06\[0.70,1.61\]   58/0.09       1.05\[0.77,1.43\]   46/0.160   0.60\[0.29,1.26\]       21/0.28       1.04\[0.75,1.43\]   20/0.290   1.03\[0.50,2.16\]   29/0.24
  Taqman                  1        1.21\[0.96,1.52\]   \#            1.13\[0.95,1.36\]   65/0.060   0.57\[0.26,1.24\]       \#            1.49\[1.13,1.96\]   \#         0.62\[0.28,1.37\]   \#

Abbreviations: CI, confidence interval; OR, odds ratio; Ph, P value for heterogeneity from Q-test; I2, the proportion of the total variation across studies due to heterogeneity.

\#No heterogeneity was observed for only one study.

Significant results are marked in bold.
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Publication bias {#s2_3}
----------------

No publication bias was detected among studies regarding the association between the rs1501299 and rs2241766 polymorphisms (P~rs1501299~=0.088; P~rs2241766~= 0.799) and CAD risk in diabetic patients (Figure [7](#F7){ref-type="fig"}, [8](#F8){ref-type="fig"}).

![Forest plot for rs1501299 TT VS GG total](oncotarget-08-51994-g006){#F6}

![Begg\'s funnel plot of rs1501299 for contrast in overall analysis in recessive model\
Each point represents a separate study for the indicated association. Size graph symbol by weighs. Log \[OR\] natural logarithm of OR. Horizontal line means effect size.](oncotarget-08-51994-g007){#F7}

![Begg\'s funnel plot of rs2241766 for contrast in overall analysis in recessive model\
Each point represents a separate study for the indicated association. Size graph symbol by weighs. Log \[OR\] natural logarithm of OR. Horizontal line means effect size.](oncotarget-08-51994-g008){#F8}

DISCUSSION {#s3}
==========

Type 2 diabetes is associated with a marked increase in the risk of coronary artery disease.\[[@R16]\] In this present meta-analysis, which included 3996 cases and 8876 controls, the associations between the polymorphisms of ADIPOQ rs2241766 and rs1501299 and CAD risk in type 2 diabetic patients were analyzed. The results showed that the ADIPOQ rs2241766 polymorphism is a risk factor for developing CAD in the subgroup analysis. For rs1501299 polymorphism, a protective role of CAD in T2DM was found in different genetic models. Several meta-analysis on the association of adiponectin polymorphisms (rs2241766, rs1501299) with CAD in general population suggested that both rs2241766 and rs1501299 were significant high risk factor for CAD.\[[@R35]--[@R38]\] However, a low risk of rs1501299 for the development of CAD with type 2 diabetic patients was reported by Sun et al.\[[@R39]\], which was in accordance with our results.

Significant associations between rs2241766 polymorphism and CAD with T2DM were found in different subgroup. In the Caucasian subgroup, a 26% increased risk was detected in GT genotype, which suggests a possible contribution of ethnicity in genetic background for the development of CAD. A high risk of GG genotype in recessive genetic model was observed in the subgroup of genotyping method (PCR-RFLP), which implies different genotyping method may have an influence on the accuracy of genetic analysis. In the subgroup of sample size (more than 500), a relative low risk of GG genotype was detected, which needed further research to confer whether the sample size may have an effect on associations between rs2241766 polymorphism and CAD with T2DM. In the study by Mofarrah and colleagues, rs2241766 of ADIPOQ had a significant association with CAD and G allele carriers had an increased adjusted risk ratio of developing CAD.\[[@R30]\] Besides, rs2241766 polymorphism was significantly associated with the incidence of CAD in T2DM and it could independently alter the CAD risk in diabetic patients based on its strong association even after adjusting for several classical CAD risk factors.\[[@R11]\] Although evidences on increased risk between rs2241766 and CAD with T2DM had emerged, the underlying molecular mechanism was still unknown. The rs2241766 polymorphism located in exon 2 results in a synonymous change (G15G), and is relatively close to exon-intron boundary which may affect the splicing machinery.\[[@R31]\] There is increasing evidence that even silent mutations in coding regions might modify RNA levels by affecting splicing and thus decreasing expression of the gene.\[[@R40]\] In this regard, a bioinformatics analysis revealed a consensus sequence recognized by a functional exonic-splicing-enhancer (ESE) and 87% matched to a sequence at 4 bp in 3' from rs2241766 polymorphism.\[[@R40]\] Therefore, the rs2241766 might have an influence on the expression of adiponectin gene and associate with CAD risk in T2DM subjects.

###### Results of sensitivity analysis of meta-analysis for ADPIOQ rs1501299 polymorphisms and CAD in type 2 diabetic patients

                          T VS G                  TT+TG VS GG   TT VS TG+GG         GT VS GG   TT VS GG                                                                                  
  ----------------------- ----------------------- ------------- ------------------- ---------- ----------------------- -------------- ------------------- ---------- ------------------- ----------
  Total                   0.91\[0.78,1.07\]       64/0.003      0.95\[0.78,1.16\]   63/0.004   0.40\[0.22,0.71\]       84/0.000       1.00\[0.82,1.21\]   56/0.020   0.67\[0.54,0.83\]   36/0.120
  Mohammadzadeh2016       **0.86\[0.76,0.98\]**   **46/0.06**   0.89\[0.75,1.05\]   49/0.05    0.34\[0.19,0.60\]       84/0.000       0.95\[0.79,1.13\]   45/0.070   &                   &
  Katakami2012            0.94\[0.79,1.12\]       64/0.04       0.99\[0.80,1.23\]   61/0.009   0.39\[0.21,0.73\]       86/0.000       1.05\[0.86,1.27\]   50/0.040   &                   &
  Esteghamati2012         0.94\[0.81,1.10\]       59/0.01       0.99\[0.82,1.20\]   58/0.02    **0.47\[0.33,0.67\]**   **49/0.050**   1.04\[0.86,1.25\]   50/0.040   &                   &
  Al-Daghri2011           0.90\[0.76,1.07\]       67/0.002      0.95\[0.76,1.18\]   67/0.002   0.39\[0.20,0.74\]       86/0.000       1.00\[0.81,1.24\]   61/0.009   &                   &
  Chiodini2010            0.94\[0.79,1.12\]       63/0.006      0.98\[0.78,1.23\]   64/0.005   0.37\[0.20,0.71\]       83/0.000       1.03\[0.82,1.28\]   58/0.010   &                   &
  Qi2006                  0.92\[0.76,1.10\]       68/0.002      0.96\[0.76,1.21\]   67/0.002   0.41\[0.21,0.79\]       86/0.000       1.01\[0.81,1.26\]   61/0.009   &                   &
  Qi2005                  0.90\[0.76,1.08\]       66/0.003      0.93\[0.74,1.15\]   63/0.005   0.42\[0.22,0.81\]       86/0.000       0.97\[0.79,1.19\]   54/0.020   &                   &
  Lacquemant Swiss2004    0.91\[0.77,1.08\]       68/0.002      0.95\[0.76,1.17\]   67/0.002   0.38\[0.21,0.72\]       86/0.000       1.00\[0.81,1.23\]   61/0.009   &                   &
  Lacquemant French2004   0.89\[0.76,1.04\]       63/0.006      0.94\[0.76,1.17\]   66/0.002   0.38\[0.21,0.71\]       86/0.000       0.97\[0.80,1.18\]   57/0.020   &                   &
  Bacci2004               0.92\[0.77,1.09\]       68/0.002      0.92\[0.75,1.12\]   63/0.006   0.42\[0.22,0.78\]       86/0.000       0.97\[0.79,1.20\]   58/0.010   &                   &

Abbreviations: Ph, P value for heterogeneity from Q-test; I2, the proportion of the total variation across studies due to heterogeneity; CI, confidence interval; OR, odds ratio.

&No heterogeneity was observed in the homozygote model.

Significant results are marked in bold.

For the rs1501299 polymorphism, pooled result was only significant in homozygote model, which implied a 33% decreased risk of TT genotype in the developing of CAD in T2DM subjects. When the study of Mohammadzadeh et al.\[[@R23]\] was removed, the T allele carriers had a 14% decreased risk compared to G allele carriers. Besides, the TT genotype had a 53% decreased risk of developing CAD in T2DM patients in recessive model, if the research of Katakami et al. was moved out. The protective role of rs1501299 polymorphism is consistent to most published results. The G allele of the ADIPOQ rs1501299 is a susceptibility allele for CAD in Japanese type 2 diabetic patients reported by Katakami et al.\[[@R32]\]. A protective role of T allele of rs1501299 polymorphism in developing CAD in Iranian T2DM subjects was also reported by Esteghamati et al.\[[@R33]\]. Moreover, gender was also an important factor in the associations between rs1501299 polymorphism and CAD risk in T2DM. In the study if Qi et al.\[[@R21]\], the homozygous allele T at rs1501299 polymorphism was associated with a significantly lower risk of CAD in diabetic men. However, the frequency of T allele at position rs1501299 in female CAD patients was higher than that of T2DM patients without CAD. In different region, not only in Asian but also in Europe, T allele as an antiatherosclerotic phenotype was also widely observed, more research from other region were needed to support the result. The same as rs2241766 polymorphism, molecular mechanism of rs1501299 was hardly known. Although rs1501299 is located in an intronic region with no apparent biological function, this SNP may affect the expression level of the gene through some unknown mechanisms, or it may be in LD with undiscovered SNPs in the ADIPOQ gene or other genes with biological effects on insulin resistant.\[[@R17]\]

In haplotype analysis, the haplotypes 45T-276T and 45G-276T in compared to the referent haplotype 45T-276G was indicated a protective effect reported by Esteghamati et al.\[[@R33]\], however, in the study of Mohammadzadeh et al.\[[@R23]\], the haplotype 45G-276G indicated a protective effect against the presence of CAD in T2DM patients as compared to the reference 45T-276G haplotype. The differences in haplotypes might shed a new light on interactions between genes and epigenetic modifications.

There were several limitations in this meta-analysis. First, only English and Chinese articles were included in our study, which thus may bias the results. Second, patient heterogeneity and confounding factors might have distorted the analysis. Third, there was significant heterogeneity in some of the pooled analyses, which may have affected the meta-analysis results, even though we adopted the random effects model. Fourth, the number of included studies was relatively small in some subgroups, thus results should be interpreted with caution. In addition, the potential influence on genotype-CAD associations by environment factors is worthy of consideration.

In conclusion, Our meta-analysis suggests that the rs1501299 polymorphism may play a protective role in CAD, and the possible protective role in T allele and TT genotype in CAD patients with T2DM needs more researches. The rs2241766 polymorphism is found to be associated with a significant increase in CAD risk in Caucasian subgroup based on our analysis. Further studies are needed to confirm the prediagnostic effect of ADIPOQ gene polymorphisms in CAD risk in diabetic patients.

MATERIALS AND METHODS {#s4}
=====================

The systematic review was written in adherence to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) checklist.\[[@R24]\] Ethical approval was not necessary according to local legislation because of the type of study (meta-analysis).\[[@R25]\]

Identification of the related studies {#s4_1}
-------------------------------------

Embase, PubMed, Wangfang, VIP databases and China National Knowledge Infrastructure databases were thoroughly searched in June 2016 by the first two investigators to identify potential studies addressing the associations between the ADIPOQ polymorphisms and coronary artery disease. The terms "coronary artery disease," "coronary heart disease," "ADIPOQ," "APM," "diabetic mellitus," "T2DM," "variant," "polymorphism," and "polymorphisms" were used. The missing data (the data that we failed to identify during the electronic search) were obtained by reviewing the citations of review articles and all eligible studies.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

Studies in the meta-analysis must meet the following inclusion criteria: (1) evaluation of the association between ADIPOQ polymorphisms and coronary artery disease in diabetic patients. Subjects with T2DM were based on American Diabetes Association (ADA). The case group was T2DM patients with CAD, the criteria for CAD, conformed by coronary angiography, was ≥50% stenosis of at least one segment of a major coronary artery or its main branches. The control group consisted of T2DM subjects with normal exercise tolerance test and negative history of CAD; (2) case-control study or cohort design; (3) detailed genotype data could be acquired to calculate odds ratios (ORs) and 95% confidence intervals (CIs); Exclusion criteria: (1) duplication of previous publications; (2) comment, review and editorial; (3) study with no detailed genotype data. The selection of the studies was achieved by two investigators independently, according to the inclusion and exclusion criteria by screening the title, abstract and full-text. Any dispute was solved by discussion.

Data extraction {#s4_3}
---------------

From each study, the following data were independently extracted by the first two investigators using a standardized form: first author\'s last name, year of publication, study country, ethnicity, region, genotyping methods, Hardy--Weinberg equilibrium, number of cases and controls, genotype distribution in cases and controls for ADIPOQ, quality score. Different ethnicity descents were classified as Caucasian and Mongoloid. Disagreements were resolved through discussion with a 3rd investigator.

Quality assessment {#s4_4}
------------------

The first two authors independently assessed the quality of the included studies, according to a set of criteria ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) modified on the basis of the Newcastle-Ottawa quality assessment scale. Scores ranged from 0 to 10, with 0 as the lowest and 10 as the highest quality.

Statistics analysis {#s4_5}
-------------------

Hardy--Weinberg equilibrium (HWE) was evaluated for each study by Chi-square test in control groups, and P \< 0.05 was considered as a significant departure from HWE. Odds ratio (OR) and 95% confidence intervals (CIs) were calculated to evaluate the strength of the association between ADIPOQ polymorphisms and CAD in T2DM subjects. Pooled ORs were performed for allelic model (rs2241766: G versus T; rs1501299: T versus G), heterozygote model (rs2241766: GT versus TT; rs1501299: TG versus GG), homozygote model (rs2241766: GG versus TT; rs1501299: TT versus GG), dominant model (rs2241766: GG+GT versus TT; rs1501299: TT+TG versus GG), recessive model (rs2241766: GG versus GT+TT; rs1501299: TT versus TG+GG), respectively. The statistically significant level was determined by Z-test with P value less than 0.05. Heterogeneity was evaluated by Q statistic (significance level of P \< 0.1) and I^2^ statistic (greater than 50% as evidence of significant inconsistency). To adjust for multiple comparisons, we applied the Bonferroni method to control the false discovery rate (FDR) \[[@R26], [@R27]\].

Heterogeneity between studies was evaluated with the I^2^ test, and a higher I^2^ values means higher levels of heterogeneity (I^2^ \>90%: extreme heterogeneity; I^2^ = 70% to 90%: large heterogeneity; I^2^ =50% to 70%: moderate heterogeneity; I^2^ \< 50%: no heterogeneity). In heterogeneity evaluation, when the I^2^ \< 50%, the fixed-effects model would be used; if the I^2^ =50% to 90%, a random-effects model was used; if the I^2^ \> 90%, the studies would not be pooled.\[[@R28]\] If heterogeneity was significant, sensitivity analysis was performed to detect the heterogeneity by omitting each study in each turn. Besides, subgroup analyses were stratified by ethnicity (Caucasian, Mongoloid), region (Eastern Asian, West Asian, Southern Europe, North Europe), sample size(more than 500, less than 500), genotyping method(PCR-RFLP, PCR-HRM, PCR, Taqman). The publication bias was assessed with Begg\'s funnel plot and Egg\'s test. Review Manager, Version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration; Copenhagen, Denmark) was used for all analysis.
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